IDEXX expands Fecal Dx platform with taeniid tapeworm detection
The expansion adds detection of Taenia and Echinococcus species, broadening intestinal parasite screening in routine care.
See the latest news and media coverage for IDEXX. We track all announcements, press releases, and industry mentions in real time, all in one place.
Veterinary diagnostics and practice management company
idexx.comLast updated
In short: IDEXX reported strong Q1 2026 financial growth, raised its full-year guidance, and announced Michael Erickson as the next President and CEO.
The expansion adds detection of Taenia and Echinococcus species, broadening intestinal parasite screening in routine care.
Reports 14% revenue growth to $1,141 million, EPS of $3.47 up 17%, and raises full-year guidance.
The release is scheduled for May 5, 2026, before market open, followed by an 8:30 a.m. ET conference call. Webcast available on IDEXX investor site.
Dr. Julie Levy and Dr. Melissa Beall present groundbreaking results on diagnostics and survival outcomes. Watch on-demand.
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily...
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX Laboratories (NasdaqGS:IDXX) has expanded its Fecal Dx antigen testing to detect taeniid tapeworm in companion animals.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to buy right now. On May 19, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced that...
Track IDEXX and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.